A biomarker test to measure progression for Parkinson's Disease is available in the US before 2029
Saúde e medicinaOne-Off2aManifold MarketsSem KYCDados de resolução verificadosRazoavelmente calibradoPrevisão da comunidade atualSim 71.7%
Previsores
6
Tipo de pergunta
binary
Metodologia
Play-money forecasting platform
Tipo de fonte
Previsão
Dados do mercado
Atualizado há 17 horas
Desatualizado25/04/23, 16:13 UTC2/01/29, 06:59 UTC
Tendências
Regras
There will be a test of a biomarker which meaningfully correlates with parkinson's progression for at least a signficant subset (>10% of those diagnosed clinically) of people with Parkinson's disease in the US before 2029
- examples: Patient has classic non-genetic PD from a clinical diagnosis based on symptoms (rigidity, etc.).
- There will be a test which they can take which shows the severity of the disease, and which when given repeatedly can be used to measure how much or less the disease has progressed
